Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
NCT01218880
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
M2ES 7.5mg
DRUG:
M2ES 15mg
DRUG:
M2ES 30mg
DRUG:
M2ES 45mg
Sponsor
Protgen Ltd